Boston Scientific Forgoes Cost Cuts, Predicting Stent/ICD Market Recovery
This article was originally published in The Gray Sheet
Executive Summary
Boston Scientific will maintain current cost structures in its drug-eluting stent and cardiac rhythm management businesses in the near term, anticipating both markets will soon recover from a 2006 slump
You may also be interested in...
Recent Resurgence Of Bare-Metal Stents Will Be Short-Lived, Experts Say
Bare-metal stents will be nearly extinct in five years, according to participants in a panel discussion on future drug-eluting stent utilization at the Cleveland Clinic Medical Innovations Summit on Oct. 2
Recent Resurgence Of Bare-Metal Stents Will Be Short-Lived, Experts Say
Bare-metal stents will be nearly extinct in five years, according to participants in a panel discussion on future drug-eluting stent utilization at the Cleveland Clinic Medical Innovations Summit on Oct. 2
Boston Scientific Pursues Cost Cutting, Asset Sales
Boston Scientific plans to cut costs to address the reality that its core implantable defibrillator and drug-eluting stent businesses have not rebounded as predicted at the beginning of the year